- Home
- GLPG vs HOG Comparison
GLPG vs HOG Comparison
Compare GLPG & HOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | HOG |
|---|---|---|
| Founded | 1999 | 1903 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Motor Vehicles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | HOG |
|---|---|---|
| Price | $34.53 | $20.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $31.33 | $27.43 |
| AVG Volume (30 Days) | 98.5K | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.76 | N/A |
| Revenue Next Year | $0.49 | $3.87 |
| P/E Ratio | ★ N/A | $7.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.59 | $19.33 |
| 52 Week High | $37.78 | $31.25 |
Technical Indicators
Market Signals| Indicator | GLPG | HOG |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 50.06 |
| Support Level | $33.39 | $19.49 |
| Resistance Level | $34.22 | $20.84 |
| Average True Range (ATR) | 0.62 | 0.85 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 79.83 | 59.06 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About HOG Harley-Davidson Inc.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.